Health & Biotech

Managing change in regulated, fast-evolving markets.

Sector Context

The science in most mid-stage biotechs is world-class. The organizational infrastructure to coordinate it across functions — on time and within budget — usually isn’t.

Life sciences leaders are navigating a familiar tension at growing scale: 56% of biopharma executives say they’re rethinking R&D and portfolio strategy heading into 2026, while 37% name supply chain resilience a top priority and 47% cite pricing and market access pressure.[1] None of that is a science problem — it’s a coordination problem. The organizations managing it well have built the cross-functional infrastructure to move decisions at the pace clinical timelines require; the ones managing it poorly are relying on the same informal, ad hoc coordination that worked at a smaller scale and doesn’t anymore. Regulatory complexity compounds the challenge: FDA review requirements keep growing more demanding, and life sciences companies without process discipline built into (not layered onto) their compliance approach fall behind on both timeline and cost.[2] The scientific opportunity is significant. The organizational systems required to advance programs through development, approval, and scale often are not keeping pace.

Where leaders get stuck

Biggest Challenges We See
in the Health & Biotech Space

Functional silos blocking clinical program coordination

Clinical development requires coordination across internal clinical operations, regulatory, manufacturing, quality, data management, and biostatistics — plus external CROs and sites. Most biotechs approach this informally, relying on bilateral conversations and ad hoc meetings rather than designed governance. Decisions move sequentially instead of concurrently. Gaps get discovered late. Programs fall behind schedule not because of the science but because the right people weren’t aligned at the right time, and no one owned the end-to-end outcome.

Research culture resisting the discipline of development

When biotech companies transition from research-stage to development-stage operations, the cultural shift is as consequential as the operational one. Research culture values exploration and scientific freedom. Development culture requires documentation, process rigor, and compliance. Most organizations try to manage this by rolling out new procedures and training. They get surface-level adoption and deep cultural resistance. Scientists who view regulatory requirements as bureaucratic overhead produce documentation that satisfies no one — not the team, and not the FDA.

HoW Rooted Fits

How Rooted Helps Leaders in the Industry

ONA is the right diagnostic for biotech. Programs succeed or fail based on cross-functional coordination, and understanding actual information flow — not the governance diagram — is essential before redesigning how teams work. OCM addresses the research-to-development cultural transition directly. The goal isn’t compliance training. It’s shifting the internal narrative from “process slows science” to “process discipline is what gets therapies to patients.” That shift requires organizational work — not just new documentation requirements.

Organizational Network Analysis (ONA)

Health & Biotech

Technology organizations make critical decisions through informal networks that bear no resemblance to the org chart. ONA maps who actually influences technical direction, where coordination breaks down across engineering, product, and security, and which informal leaders hold key workflows together.
Decision authority mapping across technical teams
Engineering-product-security coordination gap analysis
Informal influence network identification
Knowledge concentration and succession risk assessment

Business Process Engineering (BPE)

Health & Biotech

Feature delivery slowdowns rarely stem from technical problems. BPE maps actual delivery workflows and redesigns them to eliminate approval bottlenecks, clarify decision authority, and reduce cross-departmental negotiation that delays releases without improving outcomes.
Feature delivery workflow redesign
Cross-functional approval process optimization
AI integration workflow development
Security review process restructuring

Organizational Change Management (OCM)

Health & Biotech
Development culture doesn’t change through training mandates. OCM handles harder transitions — security-first development, AI-integrated workflows, new delivery models — by addressing how teams understand their work and role, not just what procedures they’re required to follow.
Security culture development in engineering
AI workflow adoption strategy and implementation
Development team change communication
Agile and delivery model transition management

Organizational Development & Effectiveness (OD&E)

Health & Biotech

Technology organizations scale headcount quickly and organizational capability slowly. OD&E builds the structures and knowledge transfer systems that let engineering and product organizations grow without losing delivery velocity, institutional knowledge, or the informal coordination that early teams depended on.
Engineering knowledge transfer system design
Organizational scaling architecture
Technical leadership development
Decision framework documentation and distribution

Common Scenarios

How We’ve Helped Health & Biotech Organizations with their Operations

Sector-Based Scenarios. Tangible Outcomes.

A gene therapy company advancing their lead program through IND-enabling studies was six months behind schedule and burning capital faster than projected. The science was solid. The team was capable. Through ONA, we found the problem: program coordination required alignment across seven functional leads, but there was no regular forum where they all came together. Decisions moved through sequential bilateral conversations — each one creating inconsistencies the next conversation had to unwind. We didn’t add program management overhead. We redesigned coordination structures to create systematic cross-functional alignment at the right intervals. The program accelerated and reached IND filing ahead of its revised timeline. The change that made the difference wasn’t technical. It was organizational.

Scale Happens Fast.
Culture Breaks Faster.

At Rooted, we help tech companies grow without fracturing their teams. As headcount doubles and processes multiply, we guide organizations through transformation using strategies that preserve what made you successful. We see the patterns, then we help you scale smartly.